Learn

The emergence of novel monoclonal antibodies targeting amyloid‐β (mABs) has generated community anticipation around treatments that may slow the progression of Alzheimer disease. Some of these antibodies have been approved by the United States Food and Drug Administration and are under review in Australia. However, their efficacy needs to be carefully balanced against treatment risks and burden. Physicians caring for patients with Alzheimer disease will require new skills when considering these competing notions. This is challenging as clinical experience is limited, and the information necessary for thoughtful decision making is often not presented in a patient‐focused manner. In this perspective article, written by clinicians and people impacted by dementia, we highlight recent data regarding mABs and discuss the impact within a patient‐centric framework. Finally, we provide guidance on how to convey this information to individuals with Alzheimer disease and their carers and families.

This MJA Perspective shares more.

Details

Authors: Oneil G Bhalala, Jane Thompson, Rosie Watson and Nawaf Yassi

Article Type: Perspective